HighFive cells (sometimes referred to as High-Five or Hi5) represent a safe, effective and inexpensive platform for protein production.
Indeed, their remarkable ability to produce very large amounts of recombinant proteins – such as diagnostic reagents and recombinant vaccines – remains unmatched.
The HighFive cells were originaly isolated from insects in BTI’s Granados lab in the late 1980’s.
Virus-free sub-clones of the original HighFive cells can be obtained from BTI or commercial partners for testing for non-commercial use, and affordable and flexible commercial licenses can be obtained from BTI.
A tested platform for protein production
- Hundreds of labs around the world use these cells.
- HighFive cell lines were used to produce an FDA-approved human vaccine. Additional human and animal vaccines expressed in HighFive cells or virus-free sub-clones are currently at various stages of the regulatory approval process.
- HighFive cells are not known to potentially host any human pathogens.
- The original HighFive cells were found to host a non-pathogenic nodavirus. BTI researchers have developed several sub-clones that are virus-free and available for licensing.
True scalability with unmatched yields
- The baculovirus expression vector system (BEVS) in insect cells offers highly scalable and inexpensive protein production. HighFive cells and sub-clones have been reported to produce 2-10x high levels of recombinant proteins compared to Sf9/Sf21 insect cells.
Proteins with less contaminants
- When considering BEVS for protein expression, Sf9/Sf21 produce very high titers of baculoviruses. That can represent a major drawback during protein purification. Purifying proteins produced in HighFive cells is preferable, with as much as 100-fold less baculovirus produced.
Affordable licensing with peace of mind
- BTI is the sole proprietor of HighFive cells and related sub-clones.